Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience

Table 1 CMV proportions and rates by covariates

	Total n	Number with CMV (%)	CMV rate per 100,000 patient days (95% CI)	p-value
Total	435	70 (16.1)	18.2 (14.7, 22.5)
Sex
Female	164	27 (16.5)	19.1 (13.6, 26.7)	0.893
Male	272	43 (15.9)	17.6 (13.4, 23.3)
Age 65 and over
< 65	396	58 (14.7)	16.4 (13.0, 20.7)	0.019
≥ 65	39	12 (30.8)	46.1 (26.8, 79.4)
Transplant Hospital
SCGH	232	33 (14.2)	14.60 (10.58, 20.16)	0.296
RPH	206	40 (19.4)	22.53 (16.93, 29.99)
Index graft history
First graft	384	64 (16.7)	18.8 (15.0, 23.5)	0.425
Had previous graft(s)	51	6 (11.8)	14.1 (7.0, 28.2)
Number of grafts during follow up
Single graft	432	69 (16.0)	18.0 (14.5, 22.3)	0.410
Two grafts	3	1 (33.3)	191.2 (26.9, 1357.4)
Donor & recipient CMV status (n = 430)
D⁻R⁻	49	0 (0)	0	<0.001
D⁻R⁺	115	13 (11.3)	11.0 (6.5, 18.6)
D⁺R⁻	68	25 (36.8)	56.8 (40.0, 80.8)
D⁺R⁺	195	32 (16.4)	18.9 (13.8, 25.9)
HLA mismatch (index graft) (n = 432)
< 2 mismatches	58	5 (8.6)	8.3 (3.7, 18.5)	0.153
≥ 2 mismatches	371	65 (17.5)	20.2 (16.2, 25.2)
Antibody treatment
None or before or at transplant only	394	59 (30.3)	15.0 (8.5, 26.5)
Post-transplant	33	11 (33.3)	18.8 (15.0, 23.7)	0.687
Rejection (any)
No	342	51 (14.9)	16.3 (12.6, 21.1)	0.205
Yes	93	19 (20.4)	35.3 (16.6, 35.3)
Rejection (severe)
No	407	63 (15.5)	16.7 (13.3, 21.1)	0.002
Yes	28	7 (25.0)	38.3 (21.7, 67.4)
Aboriginal
No	386	63 (16.3)	18.3 (14.6, 22.9)	0.838
Yes	49	7 (14.3)	17.6 (9.2, 33.8)
Donor aged >60
No	317	40 (12.6)	12.9 (9.6, 17.2)	0.002
Yes	118	30 (25.2)	36.4 (26.5, 50.0)
Deceased donor
No	192	25 (13.0)	11.4 (7.8, 16.8)	0.017
Yes	244	45 (18.5)	24.8 (19.2, 32.1)

ISSN: 1471-2334